CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based ...

3D bioprinting has the potential to impact on vast addressable markets, ultimately estimated to be in excess of $150B. With a reasonable estimate of market size forecast at $6B by the next decade, 3D ...

A cutting-edge review explores the convergence of three-dimensional (3D) printing and peptide self-assembly, unveiling a new era in biomanufacturing. This technology paves the way for creating ...

GelMA is a polymerizable hydrogel material generated from natural extracellular matrix (ECM) components. Gelatin has become popular for tissue engineering applications due to its low cost, ...

Bioprinting is an additive manufacturing (AM) method for producing biological materials that can be used in medicine, as well as other industries. In the latest advance in this relatively new field, ...

TissueFab ® GelMA-Vis-LAP bioink is a gelatin methacryloyl (GelMA)-based bioink designed for 3D bioprinting applications. In this process, LAP is employed as the photoinitiator, facilitating blue ...

REHOVOT, Israel, Nov. 15, 2021 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue ...

Precision medicine is, broadly speaking, a sweeping aspiration that will be achieved, or not, depending on the convergence of many different disciplines. The most important of these disciplines are ...

The Swedish company that commercialized the first bio-based ink in 2016 has moved far beyond bioprinting and on-demand biofabrication of human organs and tissues—especially after completing six ...

Delray Beach, FL, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The global 3D bioprinting market, valued at US$1.2 billion in 2023, stood at US$1.3 billion in 2024 and is projected to advance at a resilient CAGR ...